Core Viewpoint - The strategic merger between MicroPort Medical (00853) and CRM Cayman aims to optimize resource allocation and enhance overall competitiveness in the structural heart disease and arrhythmia management sectors, with completion expected around December 19, 2025 [1][2]. Group 1: Merger Details - The independent shareholders of MicroPort Heart have approved the merger agreement during a special meeting held on December 15, 2025, leading to the cancellation of all existing shares of CRM Cayman in exchange for ordinary shares of MicroPort Heart [1]. - Following the merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort Heart, facilitating the integration of complementary product lines and global channel resources [1]. Group 2: Strategic Focus - The company plans to leverage its accumulated expertise in interventional treatment and precision delivery within the structural heart disease business, alongside its technological advantages in AI diagnostics and algorithms in arrhythmia management, to penetrate the heart failure market [2]. - The goal is to create a comprehensive management solution covering all causes, stages, and processes of heart failure, providing complete management services from monitoring to diagnosis, treatment, and management [2]. Group 3: Financial Implications - The merger is expected to significantly optimize the consolidated financial structure of the group, as approximately $260 million in preferred stock buyback obligations will be converted into ordinary shares, effectively reducing overall debt and financial costs [2]. - Prior to the merger, CRM Cayman refinanced a convertible bond with an original principal of approximately $128 million, replacing it with a long-term bank loan at an interest rate of 2.8%, further enhancing the financial structure [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 自願公告 有關擬進行心律管理業務之策略性重組之最新情況 茲提述微創醫療科學有限公司（「本公司」，連同其附屬公司統稱為「本集團」）日期為二零二五年七月 十六日及二零二五年九月二十九日的公告（「該等公告」），內容有關本集團心律管理業務之擬議重 組。除文義另有所指外，本公告所用詞彙與該等公告所界定者具有相同涵義。 本公司董事會（「董事會」）欣然宣佈，微創心通之獨立股東已於二零二五年十二月十五日舉行的微創 心通股東特別大會上批准合併協議及其項下擬進行的交易。預期合併將於二零二五年十二月十九日 或前後完成，據此，CRM Cayman之所有現有已發行股份（包括普通股及優先股）將予以註銷，以換取 微創心通之普通股，且CRM Cayman將成為微創心通之全資附屬公司。 1 與此同時，基於結構性心臟病業務在介入治療、精密輸送與材料平台的積 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

大摩开门会：中国 AI 算力的供给及需求 251212 摘要 中国 AI 算力供不应求，尽管算法优化，AI 效率芯片仍紧缺。腾讯、阿里 巴巴等企业面临 GPU 供应限制，资本市场担忧芯片短缺，未来三年混合 云厂商资本支出预计增长至 4,500 亿人民币，但仍低于美国大厂水平。 H200 芯片在性能上领先，国内尚无替代品，需求量大。监管层或允许 企业采购 H200，以审批形式平衡模型玩家需求与国产芯片发展，放开 H200 供应将利好云厂商及下游模型和应用。 放开 H200 供应后，国内数据中心需求预计显著提高，过去需求受芯片 供给限制。推荐腾讯、阿里巴巴等超大型公司，以及 GDS、VNET 等数 据中心公司。 受 GPU 限制，中国云厂商倾向于在海外数据中心进行模型训练，国内数 据中心主要用于推理。台积电为中国市场生产芯片的计划将延续至 2026 上半年，每个 H200 中端单元成本约 1,300 美元。 中国需加强本土化生产能力，天生、阿里巴巴平头哥、百度昆仑等企业 开发专用集成电路（ASIC），调整设计以符合出口管制，减少对进口依 赖。中芯国际计划到 2027 年月产能达 3-4 万晶圆。 在 H200 板 ...

周五，大奇迹日啊！A股三大指数集体翻红，尤其是创业板指涨了近1%，两市成交额也回到了2万亿以 上。 盘面上热点轮动很快，可控核聚变、商业航天掀起了涨停潮，还得是科技成长！ 1、科技创新与高端制造 这里面还有具体细分，大家可以找找对应的ETF进行布局。 比如，人工智能与算力，会议提到了深入"人工智能+"行动； 其次，高端装备与商业航天。"实施新一轮重点产业链高质量发展行动"直接利好高端装备。国家设立商 业航天司，推动产业高质量发展，使商业航天板块近期持续受到资金关注。 港股，恒生指数涨得更带劲，全天涨了1.75%，表现比A股还强一些。整体看，市场在经历了前几天的 调整后，情绪有所回暖，资金又开始活跃起来了。 重磅经济会议落地，提到了几个重点任务，坚持内需主导、强化科技创新、建设全国统一大市场（反内 卷）、统筹发展与安全。 这里主次很明显了，后续，或者说2026年这几个方向值得重点关注： 还有，工业母机与机器人。作为智能制造的基础，工业母机被"十五五"规划列为优先方向，机器人产业 也受益于政策助推产业化落地。 2、内需与大消费 提振消费是"坚持内需主导"的核心，还有一个逻辑，部分消费板块估值已处于历史中低水平。 ...

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 310,000 shares on December 9, with a total net increase of 5.3182 million shares over the last five trading days [1] - Over the past 20 trading days, there were 15 days of net increases, totaling 14.1728 million shares [1] - As of now, southbound funds hold 907 million shares of MicroPort Medical, accounting for 47.42% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal instruments [1] - Cardiac Rhythm Management (CRM): Involves pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Includes products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Products for treating cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business: Involves transcatheter aortic valve implantation [1] - Surgical Robotics Business: Engaged in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices: Focuses on the manufacturing and R&D of surgical medical instruments [1]

证券日报网讯12月8日，建发致新（301584）在互动平台回答投资者提问时表示，公司目前供应商较为 多元化，主要供应商/生产企业包括但不限于中国的微创医疗、迈瑞医疗（300760）、归创通桥、赛诺 医疗、春立医疗，美国的美敦力、爱尔康、波士顿科学、史赛克，法国的思塔高、梅里埃等。 ...

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Group 1 - The core point of the article is the acquisition of 100% equity of MicroPort Cardiac Rhythm Management by HeartLink Medical for $680 million, structured as a "zero cash" transaction through the issuance of new shares [3][5] - The acquisition involves issuing approximately 39.54 billion new shares, which represents about 164% of HeartLink Medical's existing share capital, at a price of HKD 1.35 per share, reflecting a premium of approximately 23.85% over the closing price prior to the announcement [5][6] - Both HeartLink Medical and MicroPort Cardiac Rhythm Management are currently operating at a loss, with HeartLink reporting a loss of approximately RMB 2.2 million in the first half of the year and MicroPort Cardiac Rhythm Management reporting a loss of $41.62 million [3][8] Group 2 - The transaction is seen as a strategic move to mitigate the risks associated with a previous investment agreement that required MicroPort Cardiac Rhythm Management to go public by July 17, 2025, or face redemption risks [4][10] - The issuance of new shares will significantly dilute the holdings of existing public shareholders, reducing their ownership from 53.7% to 35.87%, a decrease of approximately 17.83 percentage points [7][6] - Despite the dilution, HeartLink Medical believes the acquisition will diversify its product offerings and enhance its global market development capabilities, as well as achieve synergies and economies of scale [7][8] Group 3 - The financial implications of the merger indicate that while HeartLink Medical's revenue may expand significantly, it will also inherit substantial losses from MicroPort Cardiac Rhythm Management, which reported revenues of approximately $207 million, $220 million, and $114 million for the years 2023-2025, with corresponding net losses of $120 million, $109 million, and $41.62 million [9][10] - The total assets of MicroPort Cardiac Rhythm Management are approximately $369 million, with total liabilities of about $734 million, indicating a challenging financial position that HeartLink Medical will need to manage post-acquisition [10] - The merger is positioned as a way for MicroPort Medical to offload a consistently loss-making business while establishing a cardiac product platform that can leverage international marketing and sales channels [10]